Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a ...
Roche announced that the European Commission has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth …